Qiagen NV

NYSE:QGEN  
48.68
-0.89 (-1.80%)
Products, Regulatory

Qiagen And Denovo Biopharma Partner To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma

Published: 12/09/2021 14:36 GMT
Qiagen NV (QGEN) - Denovo Biopharma and Qiagen Partner to Develop Companion Diagnostic Test for Treatment of Diffuse Large B-cell Lymphoma (dlbcl).
Partners Seek FDA Premarket Approval (pma) of Companion Diagnostic Test in Tandem With New Drug Application (nda) Approval.
Qiagen's Blood-based Test Will Help to Identify Patients With Diffuse Large B-cell Lymphoma (dlbcl) Likely to Respond to Denovo's New Investigational Cancer Treatment Db102.
Goal is to Get Pma for Test Contemporaneously With Denovo Receiving New Drug Application (nda) Approval for Its Db102.
Drug and Dgm1 Marker Are Currently in a Phase Iii Trial, Called Engine, on Newly Diagnosed, High-risk Dlbcl Patients.